ArticleeLife2017
Tuberculosis innovations mean little if they cannot save lives.
Article in eLife, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Chitosan as an Alternative to Oil-Based Materials for the Fabrication of Lab-on-a-Chip.Micromachines · 2024Article
- Ending tuberculosis: challenges and opportunities.Frontiers in tuberculosis · 2024Review
- Comparative analysis of CBNAAT (GeneXpert) and Ziehl-Nielsen staining test as diagnostic modalities of tuberculosis.Journal of family medicine and primary care · 2024Article
- Article
- Roadblocks and resilience: A qualitative study of the impact of pediatric tuberculosis on Tanzanian households and solutions from caregivers.Global public health · 2023Article
- Antibiotic Resistance toAntibiotics (Basel, Switzerland) · 2022Review
- Engineering a sustainable future for point-of-care diagnostics and single-use microfluidic devices.Lab on a chip · 2022Review
- Diagnostic Accuracy of the Truenat MTB Plus Assay and Comparison with the Xpert MTB/RIF Assay to Detect Tuberculosis among Hospital Outpatients in Cameroon.Journal of clinical microbiology · 2022Article
- Stabilization of Tuberculosis Reporter Enzyme Fluorescence (REFtb) Diagnostic Reagents for Use at the Point of Care.Diagnostics (Basel, Switzerland) · 2022Article
- Alterations in molecular response of Mycobacterium tuberculosis against anti-tuberculosis drugs.Molecular biology reports · 2022Review
- A new blood-based RNA signature (RiScience · 2022Article
- When it comes to stopping tuberculosis, what is actually "missing"?PLOS global public health · 2022Article
- Asia emerges as a hotbed of diagnostic innovations for tuberculosis.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
- Status and challenges for tuberculosis control in India - Stakeholders' perspective.The Indian journal of tuberculosis · 2021Article
- Translating scientific discoveries during pandemics: ensuring equity for people affected by COVID-19 and tuberculosis.ERJ open research · 2020Article
- Performance of the Roche cobas MTB Assay for the Molecular Diagnosis of Pulmonary Tuberculosis in a High HIV Burden Setting.The Journal of molecular diagnostics : JMD · 2020Article
- Advances in Molecular Diagnosis of Tuberculosis.Journal of clinical microbiology · 2020Review
- Improving quality is necessary to building a TB-free world: Lancet Commission on Tuberculosis.Journal of clinical tuberculosis and other mycobacterial diseases · 2020Review
- Rapid Tuberculosis Diagnosis Using Reporter Enzyme Fluorescence.Journal of clinical microbiology · 2019Article
- Implementation of XpertPublic health action · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past decade has seen the emergence of new diagnostics and drugs for tuberculosis, a disease that kills over 1.8 million people each year. However, these new tools are yet to reach scale, and access remains a major challenge for patients in low and middle income countries. Urgent action is needed if we are committed to ending the TB epidemic. This means raising the level of ambition, embracing innovation, increasing financial investments, addressing implementation gaps, and ensuring that new technologies reach those who need them to survive. Otherwise, the promise of innovative technologies will never be realized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.